Global pharma company to invest in Danish R&D project

The Danish biotech company Gubra is to collaborate with the medical giant Sanofi on the development of new peptide-based drugs.

A grant from the Danish National Advanced Technology Foundation has helped to pave the way for collaboration between the Danish biotech company Gubra ApS and Sanofi - a major international pharmaceutical company.

The new partnership will build on an ongoing project funded by the Danish National Advanced Technology Foundation between Gubra ApS, Gentofte Hospital and the University of Copenhagen and will provide the parties with additional research funds.

The project aims to discover new gastrointestinal hormones that can be developed into drugs to treat diabetes and obesity.

"The new partnership will result in the development of new targets and new drugs, and at Gubra we are very pleased that Sanofi has been able to see the synergy and the potential that lies in our ongoing cooperation with Gentofte Hospital and the University of Copenhagen," says Niels Wrong, CEO of Gubra.

Read more about the Danish National Advanced Technology Foundation project (IN DANISH) here.